Data from the phase 2 LUMINOSITY study support the FDA approval of telisotuzumab vedotin in this non–small cell lung cancer population.
Approval Alert | Telisotuzumab Vedotin in c-MET+ NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
2
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
3
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
4
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
5
